



Emergent BioSolutions Chief Financial Officer, Don Elsey, Named SmartCFO of the Year

June 15, 2009

ROCKVILLE, Md.--(BUSINESS WIRE)--Jun. 15, 2009-- Emergent BioSolutions Inc. (NYSE:EBS) announced today that Don Elsey, its chief financial officer (CFO) and senior vice president of finance and administration, has been named 2009 SmartCFO of the Year by SmartCEO Magazine. This annual award is based on votes from SmartCFO finalists selected from the Washington-Baltimore region in April for exhibiting exemplary skills in maintaining a company's financial integrity.

"I am deeply honored to have received this recognition from my peers," said Elsey. When asked what has been his proudest moment as CFO of Emergent, Elsey responded, "I am most proud of building an incredibly talented finance, IT, and HR team who not only supports the entire organization for growth, but also plays a vital role in making that growth possible."

Elsey's over 20 years of cumulative experience in the finance and life sciences industries have effectively contributed to the company's expansion, with Emergent posting seven consecutive years of growth and profitability. In 2006, Elsey was also instrumental in transitioning Emergent from a private to a public company.

SmartCEO Magazine recognizes that "the role of a successful chief financial officer goes far beyond finance and numbers. While finance is the main area a CFO oversees, the CFOs profiled...are effective managers, visionaries and trusted advisors to the CEO and executive management team."

"Don is definitely deserving of this award," stated Fuad El Hibri, chairman and chief executive officer of Emergent BioSolutions. "Our shared vision for growth supported by his steady stewardship of Emergent's resources has contributed greatly to our company being recognized by Wall Street as one of the top performing biopharmaceutical companies."

The selection criteria for a SmartCFO include having an overall positive impact on the company's bottom line, a unique style of cash flow management, a strong adherence to ethics and morals, and success in mergers and acquisitions, among others.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax[®] (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Source: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows
Vice President, Investor Relations
301-795-1877

BurrowsR@ebsi.com

or

Media Contact:

Tracey Schmitt
Vice President, Corporate Communications
301-795-1800

SchmittT@ebsi.com